Inmune Stock Financials

We strongly advise to harness Inmune Bio fundamental analysis to find out if markets are presently mispricing the company. Simply put you can make use of it to find out if Inmune Bio is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We have collected data for thirty-three available reported financial drivers for Inmune Bio, which can be compared to its competitors. To ensure the equity is not overpriced, please check out all Inmune Bio financials, including its cash and equivalents, cash flow from operations, and the relationship between the gross profit and debt to equity .
  
With this module, you can analyze Inmune financials for your investing period. You should be able to track the changes in Inmune Bio individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past Inmune Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Inmune Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Inmune Bio's assets may result in an increase in income on the income statement.
Chance Of Financial Distress
Less than 27
Inmune Bio has less than 27 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Inmune Bio stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Inmune Bio's official financial statements usually reflect Inmune Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inmune Bio. For example, before you start analyzing numbers published by Inmune accountants, it's critical to develop an understanding of what Inmune Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Inmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inmune Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inmune Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inmune Bio. Please utilize our Beneish M Score to check the likelihood of Inmune Bio's management to manipulate its earnings.

Inmune Bio Company Summary

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business Address225 NE Mizner
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.inmunebio.com
Phone858 964 3720
CurrencyUSD - US Dollar
You should never invest in Inmune Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Inmune Stock, because this is throwing your money away. Analyzing the key information contained in Inmune Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Inmune Bio Key Financial Ratios

Generally speaking, Inmune Bio's financial ratios allow both analysts and investors to convert raw data from Inmune Bio's financial statements into concise, actionable information that can be used to evaluate the performance of Inmune Bio over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Inmune Bio reports annually and quarterly.

Inmune Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inmune Bio's current stock value. Our valuation model uses many indicators to compare Inmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inmune Bio competition to find correlations between indicators driving Inmune Bio's intrinsic value. More Info.
Inmune Bio is currently regarded as number one stock in current ratio category among related companies. It is currently regarded as number one stock in gross profit category among related companies fabricating about  7,576  of Gross Profit per Current Ratio. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Inmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inmune Bio's earnings, one of the primary drivers of an investment's value.

Inmune Bio Market Fundamentals

 Quote6.87
 Change(%)  2.83 
 Change0.20 
 Open7.07
 Low6.87
 High7.05
 Volume18457
 ExchangeNASDAQ

About Inmune Bio Financials

What exactly are Inmune Bio Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Inmune Bio's income statement, its balance sheet, and the statement of cash flows. Potential Inmune Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Inmune Bio investors may use each financial statement separately, they are all related. The changes in Inmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Inmune Bio is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Inmune has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
Please see Risk vs Return Analysis. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Tools for Inmune Stock

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go